Recent clinical trials have explored innovative therapeutic approaches for COVID-19, focusing on the safety and efficacy of novel treatments. One study investigated zapnometinib, an oral MEK1/MEK2 inhibitor with immunomodulatory and antiviral properties, in hospitalized adults with moderate to severe COVID-19, finding no significant difference in clinical severity status at Day 15 between treatment and placebo groups, despite hints of potential benefits in certain subgroups. Another trial evaluated inhaled interferon-Î²1a (SNG001) in adults with mild-to-moderate COVID-19, showing no significant differences in adverse events or time to symptom improvement between treatment and placebo groups, but suggesting a non-statistically significant reduction in hospitalizations. Both studies, conducted across multiple countries and amidst challenges such as the emergence of the Omicron variant, highlight the complexity of developing COVID-19 treatments. They underscore the need for further research to confirm the efficacy of these novel therapeutic strategies, which target different aspects of the disease's pathogenesis and offer potential benefits in specific patient populations.